SCHEMBL13610339

SCHEMBL13610339

Fc1ccc(CSSSCc2cccs2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
RAB9A P51151 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 2/20 0.43
LMNA P02545 3/20 0.43
PKM P14618 2/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 2/20 0.43
SLC6A3 Q01959 1/20 0.41
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40
TP53 P04637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNH3 Q9ULD8 1/20 0.38
PTGS2 P35354 1/20 0.38
PLA2G7 Q13093 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262202 0.84 TAAR1 (0.46) HPGDSMN1; SMN2RAB9ATSHRPOLB
SCHEMBL1740610 0.80 IDO1 (0.50) HPGDRAB9ANPSR1ALDH1A1NPC1
SCHEMBL13610295 0.80 L3MBTL1 (0.50) HPGDSMN1; SMN2RAB9ANPSR1TSHR
SCHEMBL3236567 0.74 HPGD (0.53) HPGDSMN1; SMN2RAB9ANPSR1POLB
SCHEMBL13610449 0.73 ALDH1A1 (0.46) HPGDSMN1; SMN2RAB9ATSHRMAPK1
SCHEMBL13610429 0.71 ALDH1A1 (0.37) HPGDSMN1; SMN2RAB9ATSHRPOLB
SCHEMBL576909 0.71 IDO1 (0.54) HPGDRAB9ANPSR1ALDH1A1NPC1
SCHEMBL11445152 0.71 MEN1 (0.43) HPGDSMN1; SMN2RAB9AMAPK1POLB
SCHEMBL13610336 0.70 MEN1 (0.53) HPGDSMN1; SMN2RAB9ATSHRMAPK1
SCHEMBL8307871 0.69 HPGD (0.48) HPGDSMN1; SMN2RAB9ANPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742635-B1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES INC (US) 2018-03-07 EP disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF TST, CTH, CBS HPGD 2331/4885SMN1; SMN2 1171/4885RAB9A 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.